1. Synaptotagmin-11 regulates immune functions of microgliain vivo, Journal of Neurochemistry, DOl:10.1111/jnc.16003
2. Synaptotagmin-11 Inhibits Synaptic Vesicle Endocytosis via Endophilin A1, Journal of Neuroscience, DOI: https://doi.org/10.1523/JNEUROSCI.1348-21.2023
Organize research and academic sharing and facilitate technology exchange activities to build a platform for communication in the field of innovative drug development for degenerative diseases. By bringing cutting-edge scientific and technological achievements into the industrial park, it promotes collaboration and accelerates the transformation of innovative scientific and technological achievements.
On 10 June 2021, themed “Drug R&D Strategy and Layout for New Generation of Glucose Metabolism and Its Derived Diseases”, gathered scientists, clinicians and financial investors in the field of glucose metabolism diseases and professors from XJTLU Wisdom Lake Academy of Pharmacy. They exchanged ideas and discussed the development direction of drugs, research and development, and clinical challenges.
On 10 May 2023, Dr. Zhengming Du shared the theme of “Pharmaceutical Considerations and Technology Transfer in Chemical Drug Development” from the aspects of the trend and approach of innovative drug development, the characteristics and pharmaceutical concerns of different stages of development, and technology transfer in the development process.
On 18 October 2023, Professor Antonio Vidal-Puig attended the XJTLU Academy of Pharmacy and shared on the topic “adipose tissue expandability as determinant of Healthy/Unhealthy obesity”. His team proposed that increasing the mass and activity of human thermogenic adipose tissue may be a valuable strategy for treating obesity and its metabolic complications.
